At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
ARCT Arcturus Therapeutics Ltd.
Trading 10-29 10:04:57 EDT
12.27
+0.20
+1.66%
High12.30Low12.03Vol53.18K
Open12.07D1 Closing12.07Amplitude2.24%
Mkt Cap348.62MTradable Cap322.40MTotal Shares28.41M
T/O645.61KT/O Rate0.20%Tradable Shares26.28M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
THOMSON REUTERS  ·  10-27 04:01
Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 5, 2026
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Simply Wall St.  ·  10-13
Moderna Stock Puts MRNA Cancer Vaccine Shares Back In Focus
Arcturus Therapeutics Holdings Inc : Leerink Partners Raises Target Price to $19 from $13
THOMSON REUTERS  ·  10-09
Arcturus Therapeutics Holdings Inc : Leerink Partners Raises Target Price to $19 from $13
Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
TIPRANKS  ·  10-05
Wells Fargo Keeps Their Buy Rating on Arcturus Therapeutics (ARCT)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)
TIPRANKS  ·  09-24
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT), Teladoc (TDOC) and Zimmer Biomet Holdings (ZBH)
Arcturus Therapeutics Holdings Inc : Btig Cuts Target Price to $20 from $23
THOMSON REUTERS  ·  09-24
Arcturus Therapeutics Holdings Inc : Btig Cuts Target Price to $20 from $23
US Research Roundup-Autozone, General Mills, JPMorgan
Reuters  ·  09-24
US Research Roundup-Autozone, General Mills, JPMorgan
Arcturus Agrees to Buy myNEO, Reports Interim Liver Disorder Data
Dow Jones  ·  09-24
Arcturus Agrees to Buy myNEO, Reports Interim Liver Disorder Data
Arcturus Says ARCT-810 Phase 2 Interim Data in OTC Deficiency Show Safety, Biomarker Improvement
Reuters  ·  09-24
Arcturus Says ARCT-810 Phase 2 Interim Data in OTC Deficiency Show Safety, Biomarker Improvement
Arcturus Therapeutics - to Buy Myneo to Improve Mrna Design Quality
THOMSON REUTERS  ·  09-24
Arcturus Therapeutics - to Buy Myneo to Improve Mrna Design Quality
Arcturus Therapeutics - Arct-810 Generally Safe and Well Tolerated in Ongoing Phase 2 Study
THOMSON REUTERS  ·  09-24
Arcturus Therapeutics - Arct-810 Generally Safe and Well Tolerated in Ongoing Phase 2 Study
Arcturus Therapeutics - Announces Encouraging Interim Phase 2 Results from Arct-810 in Otc Deficiency
THOMSON REUTERS  ·  09-24
Arcturus Therapeutics - Announces Encouraging Interim Phase 2 Results from Arct-810 in Otc Deficiency
Arcturus to Present Phase 2 ARCT-810 Clinical Data in OTC Deficiency on Sept. 23
Reuters  ·  09-18
Arcturus to Present Phase 2 ARCT-810 Clinical Data in OTC Deficiency on Sept. 23
Arcturus Therapeutics to Present Ornithine Transcarbamylase (Otc) Deficiency Phase 2 Clinical Data and Provide Update on Mrna Liver Therapeutics Platform
THOMSON REUTERS  ·  09-18
Arcturus Therapeutics to Present Ornithine Transcarbamylase (Otc) Deficiency Phase 2 Clinical Data and Provide Update on Mrna Liver Therapeutics Platform
Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)
TIPRANKS  ·  09-10
Citi Keeps Their Hold Rating on Arcturus Therapeutics (ARCT)
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)
TIPRANKS  ·  09-02
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Arcturus Therapeutics (ARCT) and EyePoint Pharmaceuticals (EYPT)
Arcturus Therapeutics to Present at H.C. Wainwright Global Investment Conference
Reuters  ·  09-01
Arcturus Therapeutics to Present at H.C. Wainwright Global Investment Conference
Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
TIPRANKS  ·  08-26
Roth MKM Sticks to Their Buy Rating for Arcturus Therapeutics (ARCT)
Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
TIPRANKS  ·  08-20
Analysts Offer Insights on NA Companies: Arcturus Therapeutics (ARCT), EquipmentShare.com, Inc. (EQPT) and First Tracks Biotherapeutics Inc (TRAX)
Analysts’ Opinions Are Mixed on These NA Stocks: Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Therapeutics (ARCT) and Ceribell, Inc. (CBLL)
TIPRANKS  ·  08-11
Analysts’ Opinions Are Mixed on These NA Stocks: Cardinal Infrastructure Group, Inc. (CDNL), Arcturus Therapeutics (ARCT) and Ceribell, Inc. (CBLL)

Introduction

Company Name.
Arcturus Therapeutics Ltd.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. The company was founded in 2013 and is headquartered in San Diego, California.
Issue price:
--